Literature DB >> 14762707

Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.

Etelka Farkas1, Yiffat Katz, Sudhakar Bhusare, Reuven Reich, Gerd-Volker Röschenthaler, Martin Königsmann, Eli Breuer.   

Abstract

Overactive matrix metalloproteinases (MMPs) are associated with a variety of disease states. Therefore, their inhibition is a highly desirable goal. Yet, more than a decade of worldwide activity has not produced even one clinically useful inhibitor. Because of the crucial role of zinc in the activity of the enzyme, the design of inhibitors is usually based upon a so-called zinc binding group (ZBG). Yet, many of the hitherto synthesized potent inhibitors failed clinically, presumably because they bind stronger to metals other than zinc. We have developed in vivo potent inhibitors based on the carbamoylphosphonic group as a putative ZBG. In this paper we report stability constants for Ca(II), Mg(II), Zn(II) and Cu(II) complexes of two potent, in vivo active, MMP inhibitors, cyclopentylcarbamoylphosphonic acid (1) and 2-( N, N-dimethylamino)ethylcarbamoylphosphonic acid (2). Precipitation prevented the determination of stability constants for iron(III) complexes of1 and2. For comparison with carbamoylphosphonates1 and2, we synthesized 2-cyclohexyl-1,1-difluoroethylphosphonic acid (3), which does not inhibit MMP, and determined the stability constants of its complexes with Mg(II), Ca(II) and Zn(II). Comparison with the values obtained from the complexes of1 and2 with those from3 indicates participation of the C=O group in the metal binding of the former compounds. The complex stability orders for both1 and2 are Ca(II)<Mg(II)<Zn(II)<Cu(II). In addition, the results indicate that at pH>8 the dimethylamino group of compound2 can also participate in the binding of the transition metals Cu and Zn. On the other hand, the amino group in carbamoylphosphonic acid2 lowers the stability of the complexes with metals favoring oxygen ligands (Ca, Mg and Fe) and increases the selectivity towards Zn. These results are helpful for rationalizing the results observed on our MMP inhibitors hitherto examined, and are expected to be useful for the design of new selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14762707     DOI: 10.1007/s00775-004-0524-5

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  15 in total

1.  Solid phase combinatorial library of phosphinic peptides for discovery of matrix metalloproteinase inhibitors.

Authors:  J Buchardt; C B Schiødt; C Krog-Jensen; J M Delaissé; N T Foged; M Meldal
Journal:  J Comb Chem       Date:  2000 Nov-Dec

2.  Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.

Authors:  S Pikul; N E Ohler; G Ciszewski; M C Laufersweiler; N G Almstead; B De; M G Natchus; L C Hsieh; M J Janusz; S X Peng; T M Branch; S L King; Y O Taiwo; G E Mieling
Journal:  J Med Chem       Date:  2001-08-02       Impact factor: 7.446

3.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 4.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

5.  Sulfanyl- and selanyldifluoromethylphosphonates as a source of phosphonodifluoromethyl radicals and their addition onto alkenes.

Authors:  T Lequeux; F Lebouc; C Lopin; H Yang; G Gouhier; S R Piettre
Journal:  Org Lett       Date:  2001-01-25       Impact factor: 6.005

6.  Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.

Authors:  M Margarida Bernardo; Stephen Brown; Zhi-Hong Li; Rafael Fridman; Shahriar Mobashery
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

Review 7.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

8.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family.

Authors:  H E Van Wart; H Birkedal-Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Synthesis, Characterization, and Crystal Structure of Dicalcium Glutarylbis(phosphonate) Dihydrate: A Covalently Pillared Layer Structure with the Potential for Epitaxial Growth on Hydroxyapatite.

Authors:  Mathai Mathew; Bruce O. Fowler; Eli Breuer; Gershon Golomb; Ivan S. Alferiev; Naomi Eidelman
Journal:  Inorg Chem       Date:  1998-12-14       Impact factor: 5.165

10.  Comparison of the structures of three carboxypeptidase A-phosphonate complexes determined by X-ray crystallography.

Authors:  H Kim; W N Lipscomb
Journal:  Biochemistry       Date:  1991-08-20       Impact factor: 3.162

View more
  13 in total

1.  Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity.

Authors:  David T Puerta; Michael O Griffin; Jana A Lewis; Diego Romero-Perez; Ricardo Garcia; Francisco J Villarreal; Seth M Cohen
Journal:  J Biol Inorg Chem       Date:  2005-12-03       Impact factor: 3.358

2.  Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.

Authors:  Youxuan Li; Patrick M Woster
Journal:  Medchemcomm       Date:  2015-04-01       Impact factor: 3.597

3.  Inhibition of MMPs by alcohols.

Authors:  Arzu Tezvergil-Mutluay; Kelli A Agee; Tomohiro Hoshika; Toshikazu Uchiyama; Leo Tjäderhane; Lorenzo Breschi; Annalisa Mazzoni; Jeremy M Thompson; Courtney E McCracken; Stephen W Looney; Franklin R Tay; David H Pashley
Journal:  Dent Mater       Date:  2011-06-14       Impact factor: 5.304

4.  3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.

Authors:  Vishal Patil; Quaovi H Sodji; James R Kornacki; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

5.  Probing the metal ion selectivity in methionine aminopeptidase via changes in the luminescence properties of the enzyme bound europium ion.

Authors:  Nitesh Sule; Raushan K Singh; Pinjing Zhao; D K Srivastava
Journal:  J Inorg Biochem       Date:  2011-09-22       Impact factor: 4.155

6.  Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors.

Authors:  Jacob D Durrant; César A F de Oliveira; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2011-06-20       Impact factor: 2.817

7.  Quantum chemical study of silanediols as metal binding groups for metalloprotease inhibitors.

Authors:  Igor S Ignatyev; Manuel Montejo; Pilar Gema Rodríguez Ortega; Juan Jesús López González
Journal:  J Mol Model       Date:  2013-01-15       Impact factor: 1.810

8.  A new methodology for monitoring the activity of cdMMP-12 anchored and freeze-dried on Au (111).

Authors:  Giuseppe Grasso; Marco Fragai; Enrico Rizzarelli; Giuseppe Spoto; Kwon Joo Yeo
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-23       Impact factor: 3.109

9.  The anti-inflammatory activity of a novel fused-cyclopentenone phosphonate and its potential in the local treatment of experimental colitis.

Authors:  Dorit Moradov; Helena Shifrin; Efrat Harel; Mirela Nadler-Milbauer; Marta Weinstock; Morris Srebnik; Abraham Rubinstein
Journal:  Gastroenterol Res Pract       Date:  2015-04-09       Impact factor: 2.260

10.  Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.

Authors:  Jacob D Durrant; César Augusto F de Oliveira; J Andrew McCammon
Journal:  J Mol Recognit       Date:  2010 Mar-Apr       Impact factor: 2.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.